Immune checkpoint inhibitors for RET fusion non-small cell lung cancer: hopes and challenges

Area of Science:

• Oncology
• Immunotherapy
• Molecular Diagnostics

Background:

• Immune checkpoint inhibitors (ICIs) are a significant advancement for advanced non-small cell lung cancer (NSCLC).
• However, NSCLC patients with specific oncogenic drivers, such as rearranged during transfection (RET) gene fusions, have been underrepresented in ICI studies.
• RET fusions occur in 1-2% of NSCLC cases, and targeted therapies like selpercatinib and pralsetinib have shown efficacy.

Purpose of the Study:

• To analyze the clinical data of ICIs in patients with RET fusion-positive NSCLC.
• To discuss the optimal timing for introducing ICIs in the treatment of RET fusion NSCLC.
• To propose future strategies for maximizing ICI efficacy in this patient population.

Main Methods:

• Retrospective analysis of clinical data from patients with RET fusion NSCLC treated with ICIs.
• Review of existing literature on ICI activity and RET-targeted therapies.
• Discussion of treatment sequencing and combination immunotherapy approaches.

Main Results:

• The efficacy of ICIs in RET fusion NSCLC remains not well characterized.
• Analysis suggests a need for specific treatment strategies for this subgroup.
• Emerging data on targeted therapies provides context for ICI use.

Conclusions:

• Further investigation is required to define the role and optimal use of ICIs in RET fusion NSCLC.
• Strategic integration of ICIs with targeted therapies may be crucial for improving outcomes.
• Future research should focus on combination immunotherapies to maximize treatment efficacy.